Join
Live feed
·
PRReleasevia Quantisnow
Ascendis Pharma A/S logo

Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-Tolerated Safety Profile

ByQuantisnow·Wall Street's wire, on your screen.
ASND· Ascendis Pharma A/S
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ASND (Ascendis Pharma A/S) and more on Quantisnow.